DekaBank Deutsche Girozentrale
DSGN icon

DekaBank Deutsche Girozentrale’s Design Therapeutics DSGN Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-18,700
Closed -$317K – 1358
2022
Q3 		$317K Hold
18,700
– – ﹤0.01% 1136
2022
Q2 		$262K Hold
18,700
– – ﹤0.01% 1138
2022
Q1 		$299K Buy
18,700
+1,700
+10% +$26K ﹤0.01% 1147
2021
Q4 		$336K Buy
+17,000
New +$292K ﹤0.01% 1176

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DekaBank Deutsche Girozentrale's DSGN Position: Q4 2022 in Review

DekaBank Deutsche Girozentrale sold out of Design Therapeutics (DSGN) in Q4 2022, closing a stake of 18,700 shares — an estimated $317K sold.

DekaBank Deutsche Girozentrale first reported a position in DSGN in Q4 2021 and held it in 4 quarters. The position peaked at $336K in Q4 2021. 83 funds tracked by Wall St. Rank hold DSGN as of Q4 2022.

  • DekaBank Deutsche Girozentrale reported no remaining Design Therapeutics position as of Q4 2022 after selling out during the quarter.
  • DekaBank Deutsche Girozentrale sold 18,700 Design Therapeutics shares in Q4 2022, an estimated $317K.
  • DekaBank Deutsche Girozentrale first reported a position in Design Therapeutics in Q4 2021 and held it in 4 quarters.
  • DekaBank Deutsche Girozentrale's Design Therapeutics position peaked at $336K in Q4 2021.
  • 83 funds tracked by Wall St. Rank held Design Therapeutics as of Q4 2022.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q4 2022, filed 1 Feb 2023.